Literature DB >> 20196102

Biology of Aurora A kinase: implications in cancer manifestation and therapy.

Dhanasekaran Karthigeyan1, Sallekoppal B Benaka Prasad, Jayasha Shandilya, Shipra Agrawal, Tapas K Kundu.   

Abstract

The Aurora A kinase belongs to serine/threonine group of kinases, well known for its role in cell cycle, especially in the regulation of mitosis. Numerous substrates of Aurora A kinase have been identified, which are predominantly related to cell cycle progression while some of them are transcription factors. Aurora A-mediated phosphorylation can either directly or indirectly regulate the function of its substrates. There are overwhelming evidences which report overexpression and gene amplification of Aurora A in several human cancers, and suggest that Aurora A could be a bona fide oncogene involved in tumorigenesis. Hence, Aurora A plays wide-ranging roles in both mitosis and its deregulation manifests in cancer progression. These observations have favored the choice of Aurora kinases as a target for cancer therapy. Recently, numerous small molecules have been discovered against Aurora kinases and many have entered clinical trials. Most of these small-molecule modulators designed are specific against either Aurora A or Aurora B, but some are dual inhibitors targeting the ATP-binding site which is highly conserved among the three human homologues of Aurora kinase. In this review, we discuss the physiological functions of Aurora A, interactions between Aurora A kinase and its cellular substrates, tumorigenesis mediated by Aurora A kinase upon overexpression, and small-molecule modulators of Aurora kinase as targets for cancer therapy.
© 2010 Wiley Periodicals, Inc.

Entities:  

Keywords:  centrosome dynamics; checkpoint; kinase inhibitors; phosphorylation; tumorigenesis

Mesh:

Substances:

Year:  2010        PMID: 20196102     DOI: 10.1002/med.20203

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  40 in total

1.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

2.  Control of Aurora-A stability through interaction with TPX2.

Authors:  Maria Giubettini; Italia A Asteriti; Jacopo Scrofani; Maria De Luca; Catherine Lindon; Patrizia Lavia; Giulia Guarguaglini
Journal:  J Cell Sci       Date:  2010-12-08       Impact factor: 5.285

3.  Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.

Authors:  Jian-Ming Sun; Li-Na Yang; Han Xu; Bin Chang; Hua-Ying Wang; Gong Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Regulation of AURKC expression by CpG island methylation in human cancer cells.

Authors:  Satoshi Fujii; Vibhuti Srivastava; Apurva Hegde; Yutaka Kondo; Lanlan Shen; Koyu Hoshino; Yvette Gonzalez; Jin Wang; Kaori Sasai; Xiaotu Ma; Hiroshi Katayama; Marcos R Estecio; Stanley R Hamilton; Ignacio Wistuba; Jean-Pierre J Issa; Subrata Sen
Journal:  Tumour Biol       Date:  2015-05-20

5.  Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.

Authors:  Carmelle Romain; Pritha Paul; Kwang Woon Kim; Sora Lee; Jingbo Qiao; Dai H Chung
Journal:  J Pediatr Surg       Date:  2013-10-05       Impact factor: 2.545

Review 6.  TPX2: of spindle assembly, DNA damage response, and cancer.

Authors:  Gernot Neumayer; Camille Belzil; Oliver J Gruss; Minh Dang Nguyen
Journal:  Cell Mol Life Sci       Date:  2014-02-21       Impact factor: 9.261

Review 7.  Aurora B kinase: a potential drug target for cancer therapy.

Authors:  Azaj Ahmed; Anas Shamsi; Taj Mohammad; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-28       Impact factor: 4.553

Review 8.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

9.  A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.

Authors:  E Raymond; J Alexandre; S Faivre; F Goldwasser; T Besse-Hammer; A Gianella-Borradori; V Jego; L Trandafir; N Rejeb; A Awada
Journal:  Invest New Drugs       Date:  2013-03-29       Impact factor: 3.850

10.  The WW-HECT protein Smurf2 interacts with the Docking Protein NEDD9/HEF1 for Aurora A activation.

Authors:  Finola E Moore; Evan C Osmundson; Jennifer Koblinski; Elena Pugacheva; Erica A Golemis; Dipankar Ray; Hiroaki Kiyokawa
Journal:  Cell Div       Date:  2010-09-08       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.